5 Amino 1MQ Capsules
Capsules & Sprays NNMT (nicotinamide N-methyltransferase) inhibitor; increases intracellular NAD+ levels, activates SIRT1, and promotes white-to-beige adipose tissue conversion (oral delivery form)
Half-life: Not fully characterized in humans Phase: Preclinical Bioavail.: Orally bioavailable (small molecule)
adipose tissue muscle liver
5-Amino 1MQ (50mg)
Metabolic Peptides NNMT (nicotinamide N-methyltransferase) inhibitor; increases intracellular NAD+ levels, activates SIRT1, and promotes white-to-beige adipose tissue conversion
Half-life: Not fully characterized in humans Phase: Preclinical Bioavail.: Orally bioavailable (small molecule)
oral administration subcutaneous injection
adipose tissue muscle liver
AOD-9604 (5mg)
Healing & Recovery Modified GH fragment (hGH 176-191); stimulates lipolysis and inhibits lipogenesis without affecting IGF-1 or insulin sensitivity
Half-life: ~30 minutes Phase: Phase II Bioavail.: Moderate (subcutaneous)
BPC-157 (10mg)
Healing & Recovery Cytoprotective agent; modulates nitric oxide (NO) system, promotes angiogenesis, and upregulates growth factor expression
Half-life: Stable in gastric juice; systemic half-life not fully characterized in humans Phase: Preclinical Bioavail.: Orally stable; systemic bioavailability under investigation
subcutaneous injection oral administration intraperitoneal injection
gastrointestinal tract tendons ligaments muscle bone
BPC-157 Capsules
Capsules & Sprays Cytoprotective agent; modulates nitric oxide (NO) system, promotes angiogenesis, and upregulates growth factor expression (oral delivery form)
Half-life: Stable in gastric juice; systemic half-life not fully characterized in humans Phase: Preclinical Bioavail.: Orally stable; demonstrates GI tract bioactivity; systemic bioavailability under investigation
gastrointestinal tract tendons ligaments muscle bone
BPC-157 Spray
Capsules & Sprays Cytoprotective agent; modulates nitric oxide (NO) system, promotes angiogenesis, and upregulates growth factor expression (intranasal delivery form)
Half-life: Stable in gastric juice; intranasal route may provide rapid systemic absorption Phase: Preclinical Bioavail.: Enhanced mucosal absorption; bypasses first-pass metabolism
intranasal administration
gastrointestinal tract tendons ligaments muscle bone brain (via olfactory pathway)
BPC/TB500 Blend
Healing & Recovery Dual mechanism: BPC-157 cytoprotective/NO system modulation combined with TB-500 actin-binding cell migration and angiogenesis promotion
Half-life: Components have distinct kinetics; BPC-157 is gastric juice-stable, TB-500 has extended intracellular activity Phase: Preclinical Bioavail.: High (subcutaneous)
gastrointestinal tract tendons ligaments muscle connective tissue skin
CJC NO DAC/Ipamorelin Blend
Growth Peptides Dual mechanism: CJC-1295 (Modified GRF 1-29) acts as GHRH analog at pituitary GHRH receptors; Ipamorelin acts as selective ghrelin mimetic at GHSR-1a. Synergistic GH release.
Half-life: CJC-1295 no DAC: ~30 minutes; Ipamorelin: ~2 hours Phase: Phase II Bioavail.: High (subcutaneous)
muscle bone adipose tissue pituitary gland
Dihexa (10mg)
Cognitive Peptides Hepatocyte growth factor (HGF) mimetic; potentiates HGF/c-Met receptor signaling to promote synaptogenesis, dendritic spine formation, and neuroplasticity
Half-life: Not fully characterized; orally active small molecule derivative Phase: Preclinical Bioavail.: Orally bioavailable (small molecule angiotensin IV derivative)
oral administration subcutaneous injection
brain hippocampus central nervous system
DSIP (5mg)
Cognitive Peptides Delta sleep-inducing peptide; modulates sleep architecture by interacting with opioid and serotonergic systems, normalizes cortisol and LH release patterns, and influences circadian rhythm regulation
Half-life: ~7-8 minutes (rapid enzymatic degradation in plasma) Phase: Preclinical Bioavail.: Low (rapid degradation); improved with intranasal or direct injection routes
intravenous injection subcutaneous injection intranasal administration
brain hypothalamus pituitary gland
Epithalon (50mg)
Anti-Aging & Longevity Telomerase activator; induces telomerase reverse transcriptase (hTERT) expression, extending telomere length and reducing markers of cellular senescence. Also modulates melatonin secretion from the pineal gland.
Half-life: Short circulating half-life (minutes); effects are mediated through gene expression changes that persist longer Phase: Preclinical Bioavail.: High (subcutaneous/intravenous)
subcutaneous injection intravenous injection
all tissues (telomere maintenance) pineal gland
GHK-Cu (100mg)
Anti-Aging & Longevity Copper peptide complex; modulates gene expression (up to 4,000 genes), promotes collagen and glycosaminoglycan synthesis, stimulates angiogenesis, and exhibits antioxidant/anti-inflammatory activity via copper ion delivery and gene regulation
Half-life: Short plasma half-life; tissue effects persist due to gene expression changes Phase: Phase II Bioavail.: Good (subcutaneous/topical); copper complex is well-absorbed
subcutaneous injection topical application intradermal injection
skin hair follicles connective tissue bone
GHK-Cu Capsules
Capsules & Sprays Copper peptide complex; modulates gene expression, promotes collagen and glycosaminoglycan synthesis, and exhibits antioxidant/anti-inflammatory activity (oral delivery form)
Half-life: Short plasma half-life; tissue effects persist due to gene expression changes Phase: Phase II Bioavail.: Oral bioavailability under investigation; copper complex absorption via GI tract
skin hair follicles connective tissue bone
GLP-1 (S) Semaglutide (5mg)
Metabolic Peptides GLP-1 receptor agonist; enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and promotes satiety via hypothalamic signaling
Half-life: ~7 days (due to albumin binding and DPP-4 resistance) Phase: FDA Approved Bioavail.: ~89% (subcutaneous); ~0.4-1% (oral with SNAC enhancer)
subcutaneous injection oral administration
pancreas (beta cells) brain (hypothalamus) adipose tissue gastrointestinal tract
GLP-1 Capsule
Capsules & Sprays GLP-1 receptor agonist; enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and promotes satiety via hypothalamic signaling (oral delivery form with absorption enhancer)
Half-life: ~7 days (due to albumin binding and DPP-4 resistance) Phase: FDA Approved Bioavail.: ~0.4-1% (oral with SNAC absorption enhancer; requires fasting conditions)
pancreas (beta cells) brain (hypothalamus) adipose tissue gastrointestinal tract
GLP-2 (T) Tirzepatide (15mg)
Metabolic Peptides Dual GIP/GLP-1 receptor agonist; activates both incretin receptors to enhance insulin secretion, reduce glucagon, slow gastric emptying, and increase satiety through complementary pathways
Half-life: ~5 days Phase: FDA Approved Bioavail.: ~80% (subcutaneous)
pancreas (beta cells) brain (hypothalamus) adipose tissue gastrointestinal tract
GLP-3 (R) Retatrutide (10mg)
Metabolic Peptides Triple GLP-1/GIP/glucagon receptor agonist; activates three metabolic hormone receptors simultaneously to enhance insulin secretion, promote satiety, and increase energy expenditure via glucagon-mediated thermogenesis
Half-life: ~6 days Phase: Phase III Bioavail.: High (subcutaneous); exact value under clinical investigation
pancreas (beta cells) brain (hypothalamus) liver adipose tissue
Glutathione (200mg)
Anti-Aging & Longevity Master intracellular antioxidant; directly scavenges reactive oxygen species, serves as cofactor for glutathione peroxidase and glutathione S-transferase, maintains redox homeostasis, and supports Phase II hepatic detoxification
Half-life: Intracellular: several hours; plasma (reduced form): ~10-15 minutes after IV Phase: Dietary supplement (generally recognized as safe) Bioavail.: Low oral bioavailability (degraded by GI peptidases); IV provides direct systemic delivery; liposomal formulations improve oral absorption
intravenous injection oral supplementation sublingual administration nebulized inhalation
all cells (cytoplasm, mitochondria) liver lungs immune cells
IGF1-LR3 (1mg)
Growth Peptides IGF-1 receptor agonist with reduced IGF-binding protein affinity; activates PI3K/Akt and MAPK/ERK pathways promoting cell proliferation and protein synthesis
Half-life: 20-30 hours (extended vs. native IGF-1 due to reduced IGFBP binding) Phase: Preclinical Bioavail.: High (subcutaneous); enhanced vs. native IGF-1
subcutaneous injection intramuscular injection
muscle bone connective tissue liver
Ipamorelin (10mg)
Growth Peptides Selective growth hormone secretagogue; agonist at ghrelin/GHS receptor (GHSR-1a) without significant effects on cortisol, prolactin, or appetite
Half-life: ~2 hours Phase: Phase II Bioavail.: High (subcutaneous)
subcutaneous injection intravenous injection
muscle bone adipose tissue pituitary gland
KPV (10mg)
Specialty Peptides Alpha-MSH C-terminal fragment; inhibits NF-kB nuclear translocation, reduces pro-inflammatory cytokine production (IL-1beta, IL-6, TNF-alpha), and modulates inflammatory signaling independent of melanocortin receptors
Half-life: Short (small tripeptide); rapidly metabolized Phase: Preclinical Bioavail.: Moderate (subcutaneous); oral bioavailability under investigation
subcutaneous injection oral administration topical application
skin gastrointestinal tract immune cells
Melanotan 2 (10mg)
Specialty Peptides Non-selective melanocortin receptor agonist; primarily activates MC1R on melanocytes to stimulate melanogenesis, also activates MC3R, MC4R, and MC5R affecting appetite, sexual function, and energy homeostasis
Half-life: ~1-2 hours Phase: Phase II Bioavail.: High (subcutaneous)
skin (melanocytes) brain (hypothalamus) adipose tissue
Methylene Blue (50mg)
Specialty Peptides Alternative mitochondrial electron carrier; accepts electrons from NADH and transfers to cytochrome c, bypassing Complex I and III blockades. Also inhibits monoamine oxidase (MAO-A) and modulates nitric oxide synthase (NOS).
Half-life: 5-6.5 hours Phase: FDA Approved Bioavail.: ~72% (oral)
oral administration intravenous injection
brain mitochondria (all cells) blood (hemoglobin)
MOTS-C (10mg)
Metabolic Peptides Mitochondrial-derived peptide; activates AMPK pathway, enhances glucose uptake and fatty acid oxidation, regulates mitochondrial and nuclear gene expression
Half-life: Not fully characterized in humans; short circulating half-life expected for unmodified peptide Phase: Phase I Bioavail.: Under investigation; systemic distribution demonstrated in animal models
subcutaneous injection intravenous injection
skeletal muscle adipose tissue liver
NAD+ (500mg)
Anti-Aging & Longevity Essential coenzyme; serves as electron carrier in mitochondrial respiration (Complex I, III, IV), activates sirtuins (SIRT1-7) for gene regulation, and acts as substrate for PARPs in DNA repair
Half-life: ~30-45 minutes (IV); intracellular NAD+ turnover is 1-2 hours Phase: Dietary supplement (generally recognized as safe) Bioavail.: Variable by route; IV provides 100% bioavailability; oral is low due to degradation in GI tract; sublingual may improve absorption
intravenous infusion oral supplementation sublingual administration
all cells (mitochondrial function) brain liver muscle
NAD+ Spray
Capsules & Sprays Essential coenzyme; serves as electron carrier in mitochondrial respiration, activates sirtuins (SIRT1-7), and acts as substrate for PARPs in DNA repair (sublingual delivery form)
Half-life: ~30-45 minutes (systemic); intracellular NAD+ turnover is 1-2 hours Phase: Dietary supplement (generally recognized as safe) Bioavail.: Improved vs. oral capsules; sublingual absorption bypasses GI degradation
sublingual administration
all cells (mitochondrial function) brain liver muscle
PT-141 (10mg)
Specialty Peptides Melanocortin receptor agonist; activates MC3R and MC4R in the central nervous system to modulate sexual arousal pathways independent of the vascular system
Half-life: ~2.7 hours Phase: FDA Approved Bioavail.: ~100% (subcutaneous)
subcutaneous injection intranasal administration
brain (hypothalamus) central nervous system
PT-141 Spray
Capsules & Sprays Melanocortin receptor agonist; activates MC3R and MC4R in the central nervous system to modulate sexual arousal pathways (intranasal delivery form)
Half-life: ~2.7 hours; intranasal route may provide faster CNS onset Phase: FDA Approved Bioavail.: Good intranasal absorption; rapid CNS access via olfactory pathway
intranasal administration
brain (hypothalamus) central nervous system
Selank (10mg)
Cognitive Peptides Tuftsin analog; modulates GABA-ergic, serotonergic, and dopaminergic neurotransmission; enhances enkephalin expression and immune function
Half-life: ~several minutes (native peptide); prolonged CNS activity due to Pro-Gly-Pro stabilization Phase: Approved in Russia Bioavail.: Good (intranasal); rapid CNS penetration via olfactory pathway
intranasal administration subcutaneous injection
brain central nervous system immune system
Selank Spray
Capsules & Sprays Tuftsin analog; modulates GABA-ergic, serotonergic, and dopaminergic neurotransmission; enhances enkephalin expression and immune function (intranasal delivery form)
Half-life: ~several minutes (native peptide); prolonged CNS activity; intranasal route enables rapid onset Phase: Approved in Russia Bioavail.: Good (intranasal); rapid CNS penetration via olfactory pathway
intranasal administration
brain central nervous system immune system
Semax (10mg)
Cognitive Peptides ACTH(4-7) analog with Pro-Gly-Pro extension; upregulates BDNF and NGF expression, modulates serotonergic and dopaminergic systems, and exhibits neuroprotective properties
Half-life: ~several minutes (native peptide); sustained CNS effects due to Pro-Gly-Pro stabilization Phase: Approved in Russia Bioavail.: Good (intranasal); penetrates blood-brain barrier via olfactory pathway
intranasal administration subcutaneous injection
brain central nervous system
Sermorelin (10mg)
Growth Peptides GHRH analog (first 29 amino acids of endogenous GHRH); stimulates pituitary somatotrophs to produce and release growth hormone in a pulsatile manner
Half-life: 10-20 minutes Phase: FDA Approved Bioavail.: High (subcutaneous)
subcutaneous injection intravenous injection
muscle bone pituitary gland
SNAP-8 (10mg)
Specialty Peptides SNARE complex modulator; competes with SNAP-25 for binding in the SNARE complex, reducing vesicle fusion and neurotransmitter (acetylcholine) release at the neuromuscular junction, thereby reducing muscle contraction
Half-life: N/A (topical cosmeceutical; not systemically absorbed) Phase: Cosmeceutical (not FDA regulated as drug) Bioavail.: Topical penetration only; not intended for systemic absorption
skin neuromuscular junction (topical application)
TB-500 (5mg)
Healing & Recovery Actin-binding protein; promotes cell migration, angiogenesis, and differentiation by sequestering G-actin monomers
Half-life: Not fully characterized; effects observed over days due to intracellular actin-binding activity Phase: Preclinical Bioavail.: High (subcutaneous)
subcutaneous injection intramuscular injection
muscle connective tissue skin blood vessels cardiac tissue
Tesamorelin (10mg)
Growth Peptides GHRH analog with trans-3-hexenoic acid modification; stimulates endogenous GH synthesis and release, reduces visceral adipose tissue
Half-life: 26 minutes Phase: FDA Approved Bioavail.: High (subcutaneous)
adipose tissue pituitary gland muscle brain
Thymalin (10mg)
Anti-Aging & Longevity Thymic polypeptide complex; restores thymic function, normalizes T-cell subpopulations, and modulates neuroendocrine-immune interactions
Half-life: Not fully characterized (polypeptide complex) Phase: Approved in Russia Bioavail.: High (intramuscular/subcutaneous)
intramuscular injection subcutaneous injection
immune system thymus neuroendocrine system
Thymosin Alpha 1 (10mg)
Anti-Aging & Longevity Immunomodulator; enhances T-cell differentiation and maturation, promotes dendritic cell activation via TLR signaling, modulates Th1/Th2 cytokine balance, and augments NK cell activity
Half-life: ~2 hours Phase: Approved internationally (marketed as Zadaxin) Bioavail.: High (subcutaneous)
immune system thymus lymph nodes spleen
VIP (10mg)
Specialty Peptides Neuropeptide; binds VPAC1 and VPAC2 receptors to activate adenylyl cyclase/cAMP signaling, causing vasodilation, smooth muscle relaxation, immunomodulation, and neurotransmission modulation
Half-life: ~1-2 minutes (rapid enzymatic degradation in plasma) Phase: Preclinical Bioavail.: Low (rapid degradation); typically requires direct injection or inhalation
intravenous injection subcutaneous injection nebulized inhalation intranasal administration
gastrointestinal tract lungs immune system nervous system blood vessels
